3-甲基-4-氰基吡啶 | 7584-05-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-甲基-4-氰基吡啶
• 中文别名: 4-氰基-3-甲基吡啶；3-甲基-4-吡啶甲腈
• 英文名称: 3-methyl-4-cyanopyridine
• 英文别名: 3-methylisonicotinonitrile；4-cyano-3-methylpyridine；3-methylpyridine-4-carbonitrile；3-Methyl-4-cyan-pyridin；3-Methyl-4-cyanopyridin
• CAS: 7584-05-6
• 化学式: C₇H₆N₂
• 分子量: 118.138
• InChiKey: SFNWPKSTEHBXSY-UHFFFAOYSA-N

物化性质

• 熔点：
  51-52℃
• 沸点：
  223℃
• 密度：
  1.08
• 闪点：
  90℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Methylisonicotinonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Methylisonicotinonitrile
CAS number: 7584-05-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6N2
Molecular weight: 118.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3,4-二甲基吡啶	3,4-Lutidin	583-58-4	C7H9N	107.155
  3-甲基吡啶-4-甲醛	3-methylpyridine-4-carboxaldehyde	74663-96-0	C7H7NO	121.139

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  3-(溴甲基)异烟腈	3-(bromomethyl)pyridine-4-carbonitrile	116986-14-2	C7H5BrN2	197.034
  ——	2-chloro-5-methylisonicotinonitrile	1261685-10-2	C7H5ClN2	152.583
  2-氯-3-甲基异氰吡啶	2-chloro-3-methylisonicotinonitrile	1195189-83-3	C7H5ClN2	152.583
  3-[(E)-2-(二甲基氨基)乙烯基]异烟腈	(E)-3-(2-(dimethylamino)vinyl)isonicotinonitrile	601514-61-8	C10H11N3	173.217
  N,N-二甲氨基-2-(4-氰基-3-吡啶基)乙烯	N,N-dimethylamino-2-(4-cyano-3-pyridyl)ethene	80935-76-8	C10H11N3	173.217

反应信息

• 作为反应物：
  描述：

  3-甲基-4-氰基吡啶 在 盐酸羟胺 、 碳酸氢钠 、 potassium carbonate 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 6.0h， 以56%的产率得到N-hydroxy-3-methylisonicotinimidamide
  参考文献：
  名称：

  作为 SARS-CoV-2 复制抑制剂的 1-杂芳基-2-烷氧基苯基类似物的合成、结构-活性关系和抗病毒分析

  摘要：

  严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 是 COVID-19 的病原体，已导致大流行，这仍然是一个巨大的公共卫生负担。尽管有疫苗可用，但仍然需要小分子抗病毒药物。为了确定可用于随后的命中到先导优化活动的新型和类似药物的命中物质，我们对 160 K 化合物库针对 SARS-CoV-2 进行了高通量筛选，产生了 1-杂芳基-2-烷氧基苯基类似物是一个很有前途的目标。抗病毒分析显示该化合物对各种β-冠状病毒具有活性，初步作用模式实验表明它干扰了病毒进入。系统的构效关系 (SAR) 研究表明，恶二唑部分上的 3-或 4-吡啶基部分是最佳的，而恶二唑可以被各种其他杂芳环取代。此外，烷氧基允许一些结构多样性。

  DOI：

  10.3390/molecules27031052
• 作为产物：
  描述：

  3-甲基-4-甲酸嘧啶 在 ammonium hydroxide 、 氯化亚砜 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 27.0h， 生成 3-甲基-4-氰基吡啶
  参考文献：
  名称：

  通过支架跳跃策略发现和合成6,7,8,9-四氢-5 H-吡啶并[4,3 - c ] azepin-5-one新型化学型CCR2拮抗剂

  摘要：

  趋化因子CC受体亚型2（CCR2）在包括慢性炎症，糖尿病，神经性疼痛，动脉粥样硬化和癌症在内的多种治疗领域中引起了人们对药物开发的浓厚兴趣。通过采用切开-缝制的支架跳跃策略，我们确定了一个3,4-二氢-2,6-萘吡啶-1（2 H）-one的活性支架作为中心药效基团，以衍生出新颖的CCR2拮抗剂。关于环大小和萘啶酮环上取代的系统结构-活性关系研究产生了1-芳基氨基-6-烷基杂环-6,7,8,9-四氢-5 H-吡啶基[4,3- c] azepin-5-ones是具有纳摩尔抑制活性的新型CCR2拮抗剂的化学型。该化合物中最佳的拮抗活性以化合物13a为例，该化合物结合了C-1处的3,4-二氯苯氨基和N-6处的3-（4-（N-甲基甲基磺酰胺基）哌啶-1-基）丙基的最佳取代基位置，IC 50值为61 nM，CCR2的选择性是CCR5的10倍。建立了有效而通用的合成方法，以构建创新的核心结构并推导化合物集合。这是关于我们设计的6

  DOI：

  10.1016/j.bmc.2018.05.027

文献信息

• Lewis Basic Salt-Promoted Organosilane Coupling Reactions with Aromatic Electrophiles
  作者：Tyler W. Reidl、Jeffrey S. Bandar

  DOI：10.1021/jacs.1c05764

  日期：2021.8.11

  Lewis basic salts promote benzyltrimethylsilane coupling with (hetero)aryl nitriles, sulfones, and chlorides as a new route to 1,1-diarylalkanes. This method combines the substrate modularity and selectivity characteristic of cross-coupling with the practicality of a base-promoted protocol. In addition, a Lewis base strategy enables a complementary scope to existing methods, employs stable and easily

  路易斯碱性盐促进苄基三甲基硅烷与（杂）芳基腈、砜和氯化物的偶联，作为制备 1,1-二芳基烷烃的新途径。该方法将交叉耦合的底物模块化和选择性特征与碱基促进协议的实用性结合起来。此外，路易斯碱策略能够对现有方法进行补充，采用稳定且易于制备的有机硅烷，并在酸性官能团存在下实现选择性芳基化。该方法的实用性通过药物类似物的合成及其在多组分反应中的应用得到证明。
• Metal-free electrochemical [3 + 2] heteroannulation of anilines with pyridines enabled by dual C–H radical aminations
  作者：Mu-Jia Luo、Xuan-Hui Ouyang、Yan-Ping Zhu、Yang Li、Jin-Heng Li

  DOI：10.1039/d1gc02922c

  日期：——

  electrochemical intermolecular [3 + 2] heteroannulation of anilines with electron-deficient pyridines enabled by dual C–H radical aminations for producing functionally diverse benzo[4,5]imidazo[1,2-a]pyridines is described. The site-selectivity of aminations of aryl C(sp2)–H bonds relies on the electronic effect of two reaction partners: each contributed two reactive sites (a C(sp2)–H bond and a nitrogen

  一种前所未有的无金属/外部氧化剂电化学分子间 [3 + 2] 苯胺与缺电子吡啶的杂环化，通过双 C-H 自由基胺化产生功能多样的苯并 [4,5] 咪唑并 [1,2- a ]吡啶被描述。芳基 C(sp 2 )–H 键胺化的位点选择性依赖于两个反应伙伴的电子效应：每个都贡献了两个反应位点（一个 C(sp 2 )–H 键和一个基于氮原子的官能团）并且吡啶环4位的吸电子基团是关键。机理研究表明，该方法序列包括以氮为中心的自由基 (NCR) 和吡啶自由基阴离子的生成、自由基偶联和双 C-N 胺化。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。
• 1,2,4-oxadiazole derivatives and their therapeutic use
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2202232A1

  公开（公告）日：2010-06-30

  New derivatives of general formula (I), or pharmaceutically acceptable salts or N-oxides thereof wherein, A is selected from the group consisting of -N-, -O- and -S-; B and C are independently selected from the group consisting of-N- and -O-, with the proviso that at least two of A, B and C are nitrogen atoms; G1 is selected from the group consisting of -CH2-, -NH- and -O-; G2 is selected from the group consisting of -NR4- and -O-; R1 represents: ➢ a 8 to 10 membered bicyclic N-containing heteroaryl group optionally substituted with a C1-4 carboxyalkyl group or a C1-4 aminoalkyl group, ➢ a pyridyl group optionally substituted with one or more substituents selected from hydroxy groups, C1-4 alkyl groups, C1-4 carboxyalkyl groups, C1-4 haloalkyl groups, C1-4 alkoxy groups, amino groups, C1-4 aminoalkyl groups and C1-4 aminoalkoxy groups, ➢ a pyridone group substituted with one or more C1-4 alkyl groups; C1-4 haloalkyl groups or C1-4 aminoalkyl groups, or ➢ a group of formula: wherein: • Ra represents a hydrogen atom, a halogen atom, a C1-4 alkyl group, C3-4 cycloalkyl group or a -CF3 group; • Rb represents a hydrogen atom, a halogen atom, a C14 alkyl group, a -CF3 group or a C1-4 alkoxy group; • Rd represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; • Rc represents: ○ a hydrogen atom, a C1-4 hydroxyalkyl group, a C1-4 aminoalkyl group which is optionally substituted with one or more substituents selected from halogen atoms, hydroxy groups and -CF3 groups; ○ a 4 to 6-membered saturated N-containing heterocyclic ring optionally substituted with a C1-2 carboxyalkyl group; ○ -(CH2)(0-4)-C(O)OR', -(CH2)(0-4)-C(O)NR'R", -(CH2)(0-4)-NHC(O)R", -S(O)2NR'R", -O-(CH2)(2-4)NR'R", -O-(CH2)(1-4)C(O)OR", -O-(CH2)(1-4)-C(O)NR'R", -(CH2)(0-4)-NR'R", -(CH2)(0-4)-CONHS(O)2R', -(CH2)(0-4)-NHS(O)2R' or -(CH2)(0-3)-N H-(CH2)(1-3)-(NH)(0-1)S(O)2R' wherein, ■ R' represents a hydrogen atom or a C1-4 alkyl group, ■ R" represents a hydrogen atom, a C1-4 alkyl group, a C3-4 cycloalkyl group, a C1-4 carboxyalkyl group, a C1-4 haloalkyl group, a C1-4 hydroxyalkyl group or a 6 membered, saturated N-containing heterocyclic ring, or ■ R' and R" together with the nitrogen atom to which they are attached from a 4 to 6 membered heterocyclic group which contains, as heteroatoms, one N atom and, optionally, one further atom selected from N and O, and which is optionally substituted with a carboxy or a C1-4 carboxyalkyl group, or Rc together with Rd form a C5-6 cycloalkyl group optionally substituted by a -NHRf group, wherein Rf is selected from the group consisting of a hydrogen atom and a carboxymethyl group; R2 and R3 are independently selected from the group consisting of hydrogen atoms, halogen atoms and C1-4 alkyl groups; and R4 is selected from the group consisting of a hydrogen atom, a phenyl group, a C3-4 cycloalkyl-C1-4 alkyl group, C1-4 aminoalkyl group, C1-4 haloalkyl group and a linear or branched C1-4 alkyl group which is optionally substituted by a phenyl or a pyridyl group.

  通用公式（I）的新衍生物，或其药用可接受盐或N-氧化物，其中， A选自-N-，-O-和-S-组成的群; B和C分别选自-N-和-O-组成的群，但至少有两个A，B和C是氮原子; G1选自-CH2-，-NH-和-O-组成的群; G2选自-NR4-和-O-组成的群; R1代表: ➢一个含氮杂环的8到10成员双环基团，可选择地取代为C1-4羧基烷基基团或C1-4氨基烷基基团， ➢一个吡啶基，可选择地取代为一个或多个取代基，所选取代基包括羟基、C1-4烷基基团、C1-4羧基烷基基团、C1-4卤代烷基基团、C1-4烷氧基团、氨基、C1-4氨基烷基基团和C1-4氨氧基团， ➢一个吡啶酮基，取代为一个或多个C1-4烷基基团；C1-4卤代烷基基团或C1-4氨基烷基基团，或 ➢一个公式的基团： 其中: • Ra代表氢原子、卤原子、C1-4烷基基团、C3-4环烷基基团或-CF3基团; • Rb代表氢原子、卤原子、C14烷基基团、-CF3基团或C1-4烷氧基团; • Rd代表氢原子、C1-4烷基基团或C1-4烷氧基团; • Rc代表: ○氢原子、C1-4羟基烷基基团、C1-4氨基烷基基团，可选择地取代为一个或多个取代基，所选取代基包括卤原子、羟基和-CF3基团; ○一个4到6成员饱和的含氮杂环环，可选择地取代为C1-2羧基烷基基团; ○-(CH2)(0-4)-C(O)OR'，-(CH2)(0-4)-C(O)NR'R"，-(CH2)(0-4)-NHC(O)R"，-S(O)2NR'R"，-O-(CH2)(2-4)NR'R"，-O-(CH2)(1-4)C(O)OR"，-O-(CH2)(1-4)-C(O)NR'R"，-(CH2)(0-4)-NR'R"，-(CH2)(0-4)-CONHS(O)2R'，-(CH2)(0-4)-NHS(O)2R'或-(CH2)(0-3)-N H-(CH2)(1-3)-(NH)(0-1)S(O)2R'其中， ■ R'代表氢原子或C1-4烷基基团， ■ R"代表氢原子、C1-4烷基基团、C3-4环烷基基团、C1-4羧基烷基基团、C1-4卤代烷基基团、C1-4羟基烷基基团或6成员饱和的含氮杂环环，或 ■ R'和R"与它们连接的氮原子一起形成一个4到6成员的杂环基团，该基团包含一个N原子和可选择地一个进一步选择自N和O的原子，并可选择地取代为羧基或C1-4羧基烷基基团， 或Rc与Rd一起形成一个可选择地由-NHRf基团取代的C5-6环烷基基团，其中Rf选自氢原子和羧甲基基团; R2和R3分别选自氢原子、卤原子和C1-4烷基基团;和 R4选自氢原子、苯基团、C3-4环烷基-C1-4烷基基团、C1-4氨基烷基基团、C1-4卤代烷基基团和可选择地由苯基或吡啶基取代的线性或支链C1-4烷基基团。
• [EN] IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17<br/>[FR] IMIDAZOPYRIDAZINES EN TANT QUE MODULATEURS DE L'IL-17
  申请人：JANSSEN BIOTECH INC

  公开号：WO2021222404A1

  公开（公告）日：2021-11-04

  The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

  本申请公开了具有以下公式(I)的化合物，或其药用可接受的盐，其中R1、R2、R3、R4和R5在说明书中定义，以及制造和使用所公开化合物的方法，用于治疗或改善IL-17介导的综合征、紊乱和/或疾病。